Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma

• Status: Completed
• Trial end date: 2023-10-15
• Target enrollment: 0
• Participant gender: All

Summary

Alopecia areata (AA) is a common, immune-mediated non scarring alopecia and can be associated with severe psychological consequences . Alopecia Areata affects 2% of the global population. Alopecia Areata prevalence is lower in adults than children, is increasing over time, and significantly differs by region.

Its etiology is unknown but it was hypothesized to be an autoimmune disease mediated by T-lymphocytes. It has been suggested that inflammatory T cells induce growth arrest in hair bulbs in the anagen phase of the hair cycle . Cytotoxic T cells secrete tumor necrosis factor, granzymes, and Fas ligand which trigger apoptosis in affected hair follicle and disrupt hair growth

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Egymedicalpedia
• Treatments: Calcipotriene

Criteria

Inclusion Criteria:

• Patients with non-severe alopecia areata , a severity of alopecia tool (SALT) score up to 2 with less than 50% of scalp involvement.

• No restriction of age , race, nor occupation

Exclusion Criteria:

1. Pregnant and lactating women, immunocompromised patients.

2. Patients having active scalp inflammation.

3. Patients who received systemic treatment for Alopecia Areata in the last 3 months or applied any topical or intradermal treatments in the last 4 weeks .